Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Stilphostrol (diethylstilbestrol diphosphate) is an oral tablet containing a synthetic estrogen used historically for hormone-dependent malignancies and other estrogen-responsive conditions. The mechanism of action involves estrogen receptor activation to suppress tumor growth or manage endocrine disorders. This product represents a legacy therapeutic from the mid-20th century now being repositioned by R-Pharm US.
Pre-Launch
This pre-launch asset offers limited current commercial size; career impact depends entirely on R-Pharm US's launch strategy and regulatory approval timeline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch product presents early-stage career opportunity primarily in regulatory execution and launch planning rather than established brand growth. Current lack of linked job openings reflects pre-commercial stage; career momentum depends entirely on R-Pharm US's approval and commercialization success.
Regulatory Affairs ManagerProduct Manager
Worked on STILPHOSTROL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.